{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059674","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.690226+00:00","generated_at":"2026-06-02T03:54:40.879260+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Edgewise Therapeutics enters $175M ATM equity offering with Leerink Partners","bullets":["New Sales Agreement with Leerink Partners for at-the-market offering of up to $175M common stock.","Prior $125M ATM program with BofA Securities terminated on May 10, 2024.","Leerink will receive up to 3% commission on gross proceeds from shares sold.","Company has no obligation to sell shares and may suspend or terminate the program at any time."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059674","json":"https://secwatch.observer/filing/0001104659-24-059674.json","markdown":"https://secwatch.observer/filing/0001104659-24-059674.md","text":"https://secwatch.observer/filing/0001104659-24-059674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924059674/0001104659-24-059674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924059674/tm2413802d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:54:40.879260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43747407b154a248464035d6cb0e8dcf328f9f9c","claim":"Edgewise Therapeutics, Inc. terminated Common Stock Sales Agreement with BofA Securities, Inc. (effective 2024-05-10).","evidence_excerpt":"In connection with the Company's entry into the Sales Agreement, on May 10, 2024, the Company delivered written notice to BofA Securities to terminate the Prior Sales Agreement pursuant to Section 11(b) thereof.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924059674/0001104659-24-059674-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"BofA Securities, Inc."},{"label":"Effective","value":"2024-05-10"}],"fact_type":"material_agreement"},{"claim_id":"786f9c0805102b77c354b2a933ecd2f1293aacf8","claim":"Edgewise Therapeutics, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $175,000,000 (effective 2024-05-10).","evidence_excerpt":"On May 10, 2024, Edgewise Therapeutics, Inc. (the \"Company\") entered into a Sales Agreement (the \"Sales Agreement\") with Leerink Partners LLC (\"Leerink\") under which the Company may offer and sell shares of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), having aggregate sales proceeds of up to $175,000,000 (the \"Shares\"), from time to time, through an \"at the market offering\" program under which Leerink will act as sales agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924059674/0001104659-24-059674-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Leerink Partners LLC"},{"label":"Value","value":"up to $175,000,000"},{"label":"Effective","value":"2024-05-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}